| pubmed-article:18423639 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C1175743 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C1175175 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C1522424 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0033399 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0235828 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0598312 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C0031434 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:18423639 | lifeskim:mentions | umls-concept:C1292734 | lld:lifeskim |
| pubmed-article:18423639 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18423639 | pubmed:dateCreated | 2008-5-26 | lld:pubmed |
| pubmed-article:18423639 | pubmed:abstractText | Phenothiazine and derivatives were tested for inhibition of SARS-CoV replication. Phenothiazine slightly inhibited SARS-CoV replication in a neutral red (NR) uptake assay. Adding a propylamino group to give promazine reduced virus yields (VYR assay) with an EC(90)=8.3+/-2.8 microM, but without selectivity. Various substitutions in the basic phenothiazine structure did not promote efficacy. Phenazine ethosulfate was the most potent compound by VYR assay (EC(90)=6.1+/-4.3 microM). All compounds were toxic (IC(50)=6.6-74.5 microM) except for phenoxathiin (IC(50)=858+/-208 microM) and 10-(alpha-diethylamino-propionyl) phenothiazine.HCl (IC(50)=195+/-71.2 microM). Consequently, none were selective inhibitors of SARS-CoV replication (SI values <1-3.3 microM). These data portended the poor efficacy of promazine in a SARS-CoV mouse lung replication model. Intraperitoneal treatment with promazine using a prophylactic (-4h)/therapeutic regimen of 1, 10, or 50mg/(kg day) did not reduce virus lung titers at day 3, yet prolonged virus replication to 14 days. Similar therapeutic promazine doses were not efficacious. Thus, promazine did not affect SARS-CoV replication in vitro or in vivo, nor were any other phenothiazines efficacious in reducing virus replication. Therefore, treating SARS infections with compounds like promazine is not warranted. | lld:pubmed |
| pubmed-article:18423639 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18423639 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18423639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423639 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18423639 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18423639 | pubmed:issn | 0166-3542 | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:SakashitaGG | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:ChanPaul K... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:MontgomeryRob... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:SidwellRobert... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:BaileyKevinK | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:DayCraig WCW | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:JungKie-HoonK... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:LiJoseph... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:HeinerMatthew... | lld:pubmed |
| pubmed-article:18423639 | pubmed:author | pubmed-author:LauridsenLarr... | lld:pubmed |
| pubmed-article:18423639 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18423639 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:18423639 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18423639 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18423639 | pubmed:pagination | 105-13 | lld:pubmed |
| pubmed-article:18423639 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:meshHeading | pubmed-meshheading:18423639... | lld:pubmed |
| pubmed-article:18423639 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18423639 | pubmed:articleTitle | Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model. | lld:pubmed |
| pubmed-article:18423639 | pubmed:affiliation | Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA. dale.barnard@usu.edu | lld:pubmed |
| pubmed-article:18423639 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18423639 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
